<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01681875</url>
  </required_header>
  <id_info>
    <org_study_id>U54DA031659</org_study_id>
    <secondary_id>U54DA031659-01</secondary_id>
    <nct_id>NCT01681875</nct_id>
  </id_info>
  <brief_title>Project 1, Study 1: Investigating the Impact of Nicotine Using Spectrum Cigarettes</brief_title>
  <acronym>P1S1</acronym>
  <official_title>Project 1, Study 1: Investigating the Impact of Nicotine Using Spectrum Cigarettes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Project 1, Study 1 will evaluate the relationship between nicotine yield of very low nicotine&#xD;
      content cigarettes and cigarettes smoked per day, nicotine exposure, discomfort/dysfunction,&#xD;
      other health-related behaviors, nicotine/tobacco dependence, biomarkers of tobacco exposure,&#xD;
      intention to quit, compensatory smoking, other tobacco use, cigarette characteristics,&#xD;
      cognitive function, cardiovascular function, and perceived risk. We will also consider&#xD;
      differences between conditions in compliance with product use.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of cigarettes smoked per day</measure>
    <time_frame>End of 6 week intervention</time_frame>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">839</enrollment>
  <condition>Tobacco Dependence</condition>
  <arm_group>
    <arm_group_label>0.8 mg nicotine with 9 mg tar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>very low nicotine content cigarettes&#xD;
SPECTRUM Cigarette: 0.8 (±0.15) mg nicotine with 9 (±1.5) mg tar (standard nicotine and tar yields of commercially-available cigarettes; control condition)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.26 mg nicotine with 9 mg tar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>very low nicotine content cigarettes&#xD;
SPECTRUM Cigarette: 0.26 (±0.06) mg nicotine with 9 (±1.5) mg tar</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.12 mg nicotine with 9 mg tar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>very low nicotine content cigarettes&#xD;
SPECTRUM Cigarette: 0.12 (±0.03) mg nicotine with 9 (±1.5) mg tar</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.07 mg nicotine with 9 mg tar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>very low nicotine content cigarettes&#xD;
SPECTRUM Cigarette: 0.07 (±0.02) mg nicotine with 9 (±1.5) mg tar</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.03 mg nicotine with 9 mg tar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>very low nicotine content cigarettes&#xD;
SPECTRUM Cigarette: 0.03 (±0.01) mg nicotine with 9 (±1.5) mg tar</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.04 mg nicotine with 13 mg tar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>very low nicotine content cigarettes&#xD;
SPECTRUM Cigarette: 0.04 (±0.02) mg nicotine with 13 (±2) mg tar</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual brand</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>very low nicotine content cigarettes&#xD;
Usual brand cigarettes (control condition)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>very low nicotine content cigarettes</intervention_name>
    <arm_group_label>0.03 mg nicotine with 9 mg tar</arm_group_label>
    <arm_group_label>0.04 mg nicotine with 13 mg tar</arm_group_label>
    <arm_group_label>0.07 mg nicotine with 9 mg tar</arm_group_label>
    <arm_group_label>0.12 mg nicotine with 9 mg tar</arm_group_label>
    <arm_group_label>0.26 mg nicotine with 9 mg tar</arm_group_label>
    <arm_group_label>0.8 mg nicotine with 9 mg tar</arm_group_label>
    <arm_group_label>Usual brand</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18+&#xD;
&#xD;
          -  Smoke an average of at least five cigarettes per day for at least 1 year&#xD;
&#xD;
          -  Breath CO levels &gt; 8 ppm (if ≤ 8 ppm, then NicAlert Strip &gt; 2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intention to quit smoking in the next 30 days&#xD;
&#xD;
          -  Currently seeking treatment for smoking cessation&#xD;
&#xD;
          -  Currently using nicotine replacement therapies or other pharmacotherapies as cessation&#xD;
             aid (intermittent use acceptable)&#xD;
&#xD;
          -  A quit attempt in the past 30 days resulting in greater than 3 days of abstinence&#xD;
&#xD;
          -  Using other tobacco products more than 9 days in the past 30 days&#xD;
&#xD;
          -  Significant unstable medical conditions (Any significant change in a serious medical&#xD;
             condition occurring during the past 3 months including, cardiovascular disease, COPD,&#xD;
             and cancer, as determined by the licensed medical professional at each site)&#xD;
&#xD;
          -  Significant unstable psychiatric conditions (Any significant change in psychiatric&#xD;
             symptoms during the past 3 months as determined by the licensed medical professional&#xD;
             at each site)&#xD;
&#xD;
          -  Schizophrenia and schizoaffective disorder&#xD;
&#xD;
          -  Psychiatric medication changes in the past 3 months&#xD;
&#xD;
          -  Positive toxicology screen for any of the following drugs: cocaine, opiates,&#xD;
             methadone, benzodiazepines, barbiturates, amphetamines, methamphetamines, and PCP&#xD;
&#xD;
               1. Marijuana will be tested for but will not be an exclusionary criterion.&#xD;
&#xD;
               2. Participants with valid prescriptions for opiates, benzodiazepines, barbiturates,&#xD;
                  amphetamines or methadone will not be excluded.&#xD;
&#xD;
               3. Participants failing the toxicology screen will be allowed to re-screen once.&#xD;
&#xD;
          -  Blood alcohol level &gt; 0.01&#xD;
&#xD;
             a. Participants failing the blood alcohol screen will be allowed to re-screen once.&#xD;
&#xD;
          -  Binge drinking alcohol (more than 9 days in the past 30 days, 4/5 in a 2 hour&#xD;
             period(female/male))&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Smoking 'roll your own cigarettes' exclusively&#xD;
&#xD;
          -  Currently taking anticonvulsant medication&#xD;
&#xD;
          -  CO reading &gt;80 ppm&#xD;
&#xD;
          -  Systolic BP greater than or equal to 160&#xD;
&#xD;
             a. Participants failing for blood pressure will be allowed to re-screen once.&#xD;
&#xD;
          -  Diastolic BP greater than or equal to 100&#xD;
&#xD;
             a. Participants failing for blood pressure will be allowed to re-screen once.&#xD;
&#xD;
          -  Systolic BP below 90&#xD;
&#xD;
             a. Participants failing for blood pressure will be allowed to re-screen once.&#xD;
&#xD;
          -  Diastolic BP below 50&#xD;
&#xD;
             a. Participants failing for blood pressure will be allowed to re-screen once.&#xD;
&#xD;
          -  Heart rate greater than or equal to 115bpm&#xD;
&#xD;
             a. Participants failing for heart rate will be allowed to re-screen once.&#xD;
&#xD;
          -  Heart rate lower than 45bpm&#xD;
&#xD;
             a. Participants failing for heart rate will be allowed to re-screen once.&#xD;
&#xD;
          -  Indicating any suicidal ideation in the past month or suicide attempts in the past 10&#xD;
             years&#xD;
&#xD;
          -  Inability to independently read and comprehend the consent form and other written&#xD;
             study materials and measures&#xD;
&#xD;
          -  Having participated in a research study during the past three months in which the&#xD;
             participant:&#xD;
&#xD;
               1. Smoked a cigarette that was not his/her usual brand cigarette for more than one&#xD;
                  day&#xD;
&#xD;
               2. Used any tobacco products beyond normal use for more than one day&#xD;
&#xD;
               3. Used any nicotine replacement products or smoking cessation medications for more&#xD;
                  than one day&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric C Donny, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical School Duluth</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55812</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Donny EC, Jones M. Prolonged exposure to denicotinized cigarettes with or without transdermal nicotine. Drug Alcohol Depend. 2009 Sep 1;104(1-2):23-33. doi: 10.1016/j.drugalcdep.2009.01.021. Epub 2009 May 15.</citation>
    <PMID>19446968</PMID>
  </reference>
  <reference>
    <citation>Hatsukami DK, Kotlyar M, Hertsgaard LA, Zhang Y, Carmella SG, Jensen JA, Allen SS, Shields PG, Murphy SE, Stepanov I, Hecht SS. Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation. Addiction. 2010 Feb;105(2):343-55. doi: 10.1111/j.1360-0443.2009.02780.x.</citation>
    <PMID>20078491</PMID>
  </reference>
  <reference>
    <citation>Benowitz NL, Dains KM, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P 3rd. Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes. Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):761-9. doi: 10.1158/1055-9965.EPI-11-0644. Epub 2012 Feb 21.</citation>
    <PMID>22354905</PMID>
  </reference>
  <reference>
    <citation>Donny EC, Houtsmuller E, Stitzer ML. Smoking in the absence of nicotine: behavioral, subjective and physiological effects over 11 days. Addiction. 2007 Feb;102(2):324-34.</citation>
    <PMID>17222288</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 30, 2012</study_first_submitted>
  <study_first_submitted_qc>September 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2012</study_first_posted>
  <last_update_submitted>August 13, 2018</last_update_submitted>
  <last_update_submitted_qc>August 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biomarkers of exposure</keyword>
  <keyword>Compensatory smoking</keyword>
  <keyword>Nicotine dependence</keyword>
  <keyword>Reduced nicotine cigarettes</keyword>
  <keyword>Tobacco withdrawal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

